All News

The median overall survival was 66 months for individuals with hormone receptor-positive/human epidermal growth factor receptor-negative advanced or metastatic breast cancer administered at least 1 dose reduction of ribociclib (Kisqali) from the starting dose of 600 mg.

Individuals with elevated arterial stiffness combined with high blood pressure had the highest risk of developing type 2 diabetes.

Natalizumab (Tysarbi) is an integrin receptor antagonist indicated for treatment of: multiple sclerosis and Crohn disease.

Natrol Stress & Anxiety helps decrease the effects of stress and anxiety to aid in establishing normal sleep patterns.

Oncology pharmacists can help ensure patient access to lifesaving therapies.

The FDA approved decitabine/cedazuridine in 2020 for treatment of adults with myelodysplastic syndromes.

The application submission paves the way for a potential decision as early as this month.

Ogi Kavazovic, co-founder and CEO of House Rx, discusses the company's technology platform and pharmacy service and how it can better enable community oncology pharmacy practices to offer medically integrated dispensing.

Pharmacists can directly addressing health care disparities among socially disadvantaged and underserved communities.

The gout medicine is a potential treatment option for individuals hospitalized for the cardiovascular condition, analysis suggests.

The findings show that at 90 days, the modified Rankin Score (mRS) had a significantly greater number of individuals with an improvement of 2 points or greater.

Company releases data at the American Society of Clinical Oncology Annual Meeting 2022 showing that the drug is well-tolerated in patients with solid tumors.

There are a huge number of medical facilities in Ukraine that run international clinical trials, with the FDA noting that more than 250 drugs and devices were undergoing clinical research in Ukraine.

The new study analyzed KSHV’s latent-lytic switch, a process in which the virus exits its dormancy state to replicate in the host cell.

The safety profile of valoctocogene roxaparvovec in the phase 1/2 study was consistent with previously reported data, with no delayed-onset treatment-related adverse events (AEs).

These real-world findings help support the use of DPI in patients at increased risk of vascular events.

Pegfilgrastim-pbbk is the third oncology biosimilar developed by Amneal to gain FDA approval this year.

Ritonavir (Norvir) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

OTC Sciatica Therapy helps relieve sciatica pain, including difficulty moving, burning, and tingling in the legs, toes, and feet.

Fresh organic strawberries sold at multiple major retailers linked to multistate hepatitis A outbreak.

Fees are now so large that "hiding the cheese" will be harder to accomplish in a year and a half.

Tesh Khullar, co-founder and president of House Rx, discusses how social determinants of health can impact time to treatment initiation.

Managers can mitigate transition-related stress in new pharmacists by encouraging mentoring from senior staff.

Efforts to decrease hospital readmissions may have been misguided because the United States are already doing better than other high-income nations in this area.

The increased negative health outcomes associated with migraines provide an opportunity for pharmacists in both the inpatient and outpatient setting to support patients.

Analysis also shows a reduction in the need for opiate painkillers, and there was a decrease in other cancer-related symptoms, according to results published in Frontiers in Pain Research.

The medications are linked with reduced negative emotional bias, according to new research published in Biological Psychiatry.

Analysis provides new understanding of the effect of probiotics on the tiniest of infants in the neonatal intensive care.

In ECOSPOR III, the lead therapeutic candidate incorporated itself durably and rapidly into the microbiome to prevent recurrence, the company says.

Evinacumab-dgnb (Evkeeza) is indicated as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia.